Skip Navigation
  Search Menu
Find an Expert


Chien-Fu Hung, Ph.D.

Photo of Dr. Chien-Fu Hung, Ph.D.

Associate Professor of Pathology

Research Interests: Gene therapies; cancer vaccines; ovarian cancer immunotherapy; cancer immunology


Dr. Chien-Fu Hung is an associate professor of pathology and oncology and a professor of gynecology and obstetrics at the Johns Hopkins University School of Medicine. He is a member of the Johns Hopkins Kimmel Cancer Center. His research focuses on the prevention and treatment of cervical and ovarian cancers.

His team is currently using an ascitogenic ovarian/peritoneal tumor model to investigate DNA vaccine strategies encoding ovarian tumor antigens identified by microarray and SAGE.

Dr. Hung earned his Ph.D. in molecular biology from the University of Illinois. He completed a fellowship in pharmacology at the University of Pennsylvania and a fellowship in pathology at the Johns Hopkins University.

He received a Young Investigator Award from the Alliance for Cancer Gene Therapy in 2004. more


  • Associate Professor of Pathology
  • Associate Professor of Gynecology and Obstetrics
  • Associate Professor of Oncology

Departments / Divisions



  • Ph.D., University of Illinois (Urbana-Champaign) (Illinois) (1996)

Research & Publications

Research Summary

Cervical cancer is the second leading cause of death from cancer in women worldwide, while patients with ovarian cancer have a higher mortality rate than all other patients with gynecologic malignancies.

Dr. Hung’s research focuses primarily on developing immunotherapeutic, specifically vaccination, strategies for the prevention and treatment of cervical and ovarian cancers. His lab has developed several strategies to enhance immunologic responses against cancers. Some of these strategies involve targeting antigen into dendritic cells; targeting antigen into MHC class I and II processing pathways; enhancing intercellular spreading of antigen; and combining antigen-specific immunotherapy and antiangiogenesis.

Currently, his lab has developed an ascitogenic ovarian/peritoneal tumor model that can be used to investigate the interaction of the immune system with the establishment, progression and treatment of ovarian cancer in immunocompetent mice. Unlike models using human xenografts or human cell lines, which are limited to studies with immunocompromised mice, their model is capable of generating ascites and intraperitoneal tumor growth in immunocompetent C57BL/6 mice after intraperitoneal injection. They are presently investigating DNA vaccine strategies encoding ovarian tumor antigens identified by microarray and SAGE in this tumor model.

Selected Publications

Sun, Y. Y., Peng, S., Han, L., Qiu, J., Song, L., Tsai, Y., Yang, B., Roden, R. B., Trimble, C. L., Hung, C. F., and Wu, T. C. (2016) Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract. Clin Cancer Res 22, 657-669

Yang, A., Jeang, J., Cheng, K., Cheng, T., Yang, B., Wu, T. C., and Hung, C. F. (2016) Current State in the Development of Candidate Therapeutic HPV Vaccines. Expert Rev Vaccines

Yang MC, Yang A, Qiu J, Yang B, He L, Tsai YC, Jeang J, Wu TC, Hung C. F. (2016) Buccal injection of synthetic HPV long peptide vaccine induces local and systemic antigen-specific CD8+ T-cell immune responses and antitumor effects without adjuvant. Cell Biosci. 6:17.

Soong RS, Anchoori RK, Yang B, Yang A, Tseng SH, He L, Tsai YC, Roden RB, Hung CF. RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells. Oncotarget. 2016 Oct 18;7(42):68489-68502.

Yang A, Farmer E, Lin J, Wu TC, Hung CF. The current state of therapeutic and T cell-based vaccines against human papillomaviruses. Virus Res. 2017 Mar 2;231:148-165.

Is this you? Edit Profile